DC-CIK联合静脉化疗对晚期结肠癌患者的临床疗效观察

Clinical Efficacy of DC-CIK Combined With Intravenous Chemotherapy in Patients With Advanced Colon Cancer

目的探究DC-CIK联合静脉化疗对晚期结肠癌疗效、血清肿瘤标记物和细胞免疫应答水平的影响。方法回顾性分析89例晚期结肠癌患者资料。根据治疗方案不同,将其分为观察组(DC-CIK联合静脉化疗)和对照组(常规静脉化疗)。比较两组肿瘤标记物及免疫学指标,分析治疗效果。结果观察组有效率及疾病控制率均高于对照组(P<0.05);治疗后肿瘤标记物水平低于对照组(P<0.01);血清Th1细胞因子水平高于对照组(P<0.01),血清Th2细胞因子水平低于对照组(P<0.01)。结论 DC-CIK联合静脉化疗治疗晚期结肠癌可降低血清肿瘤标记物水平,改善细胞因子免疫应答水平,提升患者生存期,临床效果较佳。

Objective To investigate the effect of DC-CIK combined with intravenous chemotherapy on the efficacy of advanced colon cancer, serum tumor markers and cellular immune response. Methods The data of 89 patients with advanced colon cancer were retrospectively analyzed. The patients were divided into observation group （DC-CIK combined with intravenous chemotherapy） and control group （routine intravenous chemotherapy） according to different treatment options. Tumor markers and immunological indexes of two groups were compared and the therapeutic effects were analyzed. Results The efficiency and disease control rate in observation group were higher than the control group （P〈0.05）. Tumor marker level was lower than the control group after treatment （P〈0.01）. Thl cytokines level in serum was higher than that of control group （P〈0.01）. Th2 cytokines level in serum was lower than that of controt group （P〈0.01）. Conclusion DC-CIK combined with intravenous chemotherapy in advanced colon cancer can reduce the level of serum tumor markers, improve the level of cytokine immune response, and improve the survival of patients, the clinical effect is better.